Mizoribine in steroid-dependent nephrotic syndrome of childhood.
We evaluated a 1-year course of a newly developed immunosuppressant, mizoribine (at a dosage of 3 mg/kg body weight per day), in nine children with steroid-dependent nephrotic syndrome. Steroid treatment could be discontinued in two patients and the maintenance dosage of steroid could be reduced to less than half of that given before mizoribine therapy in a third. There were no beneficial effects in the remaining six patients. No adverse effects of mizoribine were observed during the course of therapy.
Hamasaki
T
T
Department of Pediatrics, Hiroshima Prefectural Hospital, Japan.
Mori
M
M
Kinoshita
Y
Y
Saeki
T
T
Sakano
T
T
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D011239:Prednisolone / Q000009:adverse effects*; D012263:Ribonucleosides / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D011239:Prednisolone